701 related articles for article (PubMed ID: 14993230)
1. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
Saltz LB; Meropol NJ; Loehrer PJ; Needle MN; Kopit J; Mayer RJ
J Clin Oncol; 2004 Apr; 22(7):1201-8. PubMed ID: 14993230
[TBL] [Abstract][Full Text] [Related]
2. A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.
Wierzbicki R; Jonker DJ; Moore MJ; Berry SR; Loehrer PJ; Youssoufian H; Rowinsky EK
Invest New Drugs; 2011 Feb; 29(1):167-74. PubMed ID: 19830388
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
Folprecht G; Lutz MP; Schöffski P; Seufferlein T; Nolting A; Pollert P; Köhne CH
Ann Oncol; 2006 Mar; 17(3):450-6. PubMed ID: 16303861
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
Gebbia V; Del Prete S; Borsellino N; Ferraù F; Tralongo P; Verderame F; Leonardi V; Capasso E; Maiello E; Bordonaro R; Stinco S; Agostara B; Barone C
Clin Colorectal Cancer; 2006 Mar; 5(6):422-8. PubMed ID: 16635281
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
7. First-line single-agent cetuximab in patients with advanced colorectal cancer.
Pessino A; Artale S; Sciallero S; Guglielmi A; Fornarini G; Andreotti IC; Mammoliti S; Comandini D; Caprioni F; Bennicelli E; Andretta V; Siena S; Sobrero A
Ann Oncol; 2008 Apr; 19(4):711-6. PubMed ID: 18073221
[TBL] [Abstract][Full Text] [Related]
8. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.
Saif MW; Kaley K; Chu E; Copur MS
Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415).
Gold PJ; Goldman B; Iqbal S; Leichman LP; Zhang W; Lenz HJ; Blanke CD
J Thorac Oncol; 2010 Sep; 5(9):1472-6. PubMed ID: 20631636
[TBL] [Abstract][Full Text] [Related]
14. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
[TBL] [Abstract][Full Text] [Related]
15. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study.
Ho C; Sangha R; Beckett L; Tanaka M; Lau DH; Eisen DB; Burich RA; Luciw P; Khan I; Mack PC; Gandara DR; Davies AM
Invest New Drugs; 2011 Aug; 29(4):680-7. PubMed ID: 20148348
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T; Emi Y; Oki E; Kobayashi K; Tsuji A; Shimokawa M; Tanaka T; Akagi Y; Ogata Y; Baba H; Yoshida K; Natsugoe S; Maehara Y;
Cancer Chemother Pharmacol; 2016 Sep; 78(3):585-93. PubMed ID: 27468920
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
Wöll E; Greil R; Eisterer W; Bechter O; Fridrik MA; Grünberger B; Zabernigg A; Mayrbäurl B; Russ G; Dlaska M; Obrist P; Thaler J
Anticancer Res; 2011 Dec; 31(12):4439-43. PubMed ID: 22199312
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.
Price TJ; Peeters M; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Zhang K; Murugappan S; Sidhu R
Lancet Oncol; 2014 May; 15(6):569-79. PubMed ID: 24739896
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.
Arnold D; Höhler T; Dittrich C; Lordick F; Seufferlein T; Riemann J; Wöll E; Herrmann T; Zubel A; Schmoll HJ
Ann Oncol; 2008 Aug; 19(8):1442-1449. PubMed ID: 18441330
[TBL] [Abstract][Full Text] [Related]
20. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
Shirao K; Yoshino T; Boku N; Kato K; Hamaguchi T; Yasui H; Yamamoto N; Tanigawara Y; Nolting A; Yoshino S
Cancer Chemother Pharmacol; 2009 Aug; 64(3):557-64. PubMed ID: 19169687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]